Buy Cipla; target of Rs 1150: Sharekhan

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Sharekhan's research report on Cipla

Cipla reported weak results for Q1FY23 on a y-o-y basis given the high base due to Covid-led demand. however sequentially, there has been a marked improvement with the operating profit and PAT staging a double digit growth. The outlook for US business is strong backed by growth in the respiratory products and high-value launches being lined up in H2FY23 in the US markets. Cipla expects to outperform the Industry growth in the domestic markets, backed by strong growth in the acute as well as chronic therapies, new brands and likely traction in consumer business.

Outlook

We maintain our Buy recommendation on Cipla Limited with an unchanged PT of Rs. 1,150. While there are near-term challenges in the form of likely cost pressures, long-term growth drivers are in place.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Cipla - 290722 - khan